["{\n\"step_by_step_thinking\": \"The question is about Ubrogepant, but none of the provided documents mention Ubrogepant. The studies discussed are about ICS 205-930, a novel 5-HT3 receptor antagonist, in the prevention of migraine attacks and experimental therapies for multiple sclerosis. There's no information about Ubrogepant. Therefore, it can be concluded that Ubrogepant has not entered clinical phase III trials.\",\n\"answer_choice\": \"B\"\n}"]